Cannatrek

Medicinal Cannabis Manufacturingcannatrek.com

Cannatrek is an Australian vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes cannabis flower and oil products through prescriber-mediated SASB and Authorised Prescriber pathways, serving AHPRA-registered doctors, nurse practitioners, pharmacists, and patients via a prescriber portal, telehealth services, and compassionate access programs.

Company typePrivate
Founded2014
HeadquartersBalaclava, Australia
Headcount51–100
GTM typeB2B and B2C
OfferingHardware or Manufacturing

What Cannatrek does

Cannatrek is an Australian vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes therapeutic cannabis products not registered on the Australian Register of Therapeutic Goods (ARTG). Its product portfolio comprises medicinal cannabis flower and oil formulations, accessed exclusively through TGA-regulated Special Access Scheme (SASB) and Authorised Prescriber pathways. The company targets AHPRA-registered prescribers (doctors and nurse practitioners) as its primary go-to-market audience, supported by a web-based Prescriber Portal offering product information, SASB and Authorised Prescriber pathway application assistance, RACGP-approved education, and a Medical Science Liaison Team for clinical engagement. Pharmacists serve as a secondary dispensing channel, with integrations including the greenship.com.au pharmacy platform.

The company's revenue model operates through prescriber-mediated access for treatment-resistant patients, supplemented by Telehealth Services for direct patient consultations and the CASP (Compassionate Access to Care Scheme) for compassionate patient access. Cannatrek is privately held (ACN 056 175 369), headquartered in Balaclava, Victoria, with operations governed under Queensland jurisdiction. In January 2026, the company announced an all-stock merger with Little Green Pharma to create a combined group with approximately A$112 million in revenue and around 80 staff, positioning the merged entity as one of the largest vertically integrated cannabis businesses globally. Customer-facing go-to-market is sales-led and prescriber-focused, with the prescriber portal, medical science liaison outreach, and RACGP-approved education forming the core commercial engine. Pricing is not publicly disclosed, reflecting the regulated nature of the channel and the absence of direct consumer retail distribution.

Cannatrek firmographics

Firmographics

Name: Cannatrek
Legal name: Cannatrek Limited
Website: https://cannatrek.com
Company type: Private
Founded year: 2014
Operating status: Operating
Headcount range: 51–100 employees
Short description: Cannatrek is an Australian vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes cannabis flower and oil products through prescriber-mediated SASB and Authorised Prescriber pathways, serving AHPRA-registered doctors, nurse practitioners, pharmacists, and patients via a prescriber portal, telehealth services, and compassionate access programs.
Ownership category
akta.pro rank

Cannatrek industry classification

Industry

Product category: Medicinal Cannabis Manufacturing
NAICS: Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC: Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro primary industry: Medical Cannabis Dispensaries (CRANAFAB)
akta.pro secondary industry: Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

Keywords

Medicinal cannabis
Cannabis cultivation
Pharmaceutical manufacturing
Prescriber services
Therapeutic goods

Where Cannatrek is headquartered

Location

Headquarters

HQ city: Balaclava
HQ country: Australia
HQ region: Oceania

Offices1 record

Markets served

Cannatrek business model

Business model

GTM type: B2B and B2C
Offering type: Hardware or Manufacturing
Cost components: Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

Medicinal cannabis products and services: Cannatrek supplies medicinal cannabis goods and services. The company operates through prescriber-mediated access pathways (SASB and Authorised Prescriber schemes), with products prescribed to treat specific conditions or symptoms where patients are treatment-resistant to recommended ARTG-registered treatments.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Cannatrek product offering

Product offering

Core offering

Cannatrek cultivates, manufactures, and distributes medicinal cannabis products (flower and oil formulations) in Australia. Products are not registered on the Australian Register of Therapeutic Goods (ARTG) and are accessed via the Special Access Scheme (SASB) or Authorised Prescriber pathways. The company also operates a prescriber portal providing healthcare practitioners with regulatory pathway assistance and RACGP-approved education.

Product overview

Cannatrek is an Australian medicinal cannabis company operating as a vertically integrated business. The company offers a portfolio of medicinal cannabis products (flower and oil formulations), a prescriber portal for healthcare providers with resources and pathway assistance, and telehealth consultation services. The CASP program provides compassionate access to care. Cannatrek products are not registered on the ARTG and must be prescribed via Authorised Prescriber or Special Access Scheme pathways. The company has agreed to merge with Little Green Pharma in an all-stock transaction to create a combined entity with A$112 million in revenue.

Differentiator

Problem solved

Functional benefit

Products and services

Medicinal Cannabis Products

Companies that use Cannatrek

Customer profile

Segments3 records

Ideal customer profiles3 records

Cannatrek technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Cannatrek partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Little Green PharmacoreStrategic or Co-development Partner · 21 January 2026Australian medicinal cannabis companies Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff, positioning the entity as one of the largest vertically integrated cannabis businesses globally.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Cannatrek competitors and assessment

Company assessment

Direct peers

Little Green Pharma: Australian medicinal cannabis cultivator, manufacturer, and distributor that is merging with Cannatrek in an all-stock deal. Operates in the same Australian regulatory framework (SASB/Authorised Prescriber), making it the most direct comparable as the merger counterparty.
Althea Group Holdings: Australian medicinal cannabis company producing and distributing THC and CBD products via similar prescriber and pharmacy channels. Directly competes with Cannatrek for Australian prescriber relationships and patient access.
AusCann Group Holdings: Australian medicinal cannabis company focused on developing, producing, and supplying cannabinoid-based pharmaceuticals. Targets the same AHPRA prescriber channel and competes for similar patient indications.
Incannex Healthcare: Australian clinical-stage medicinal cannabis and psychedelic pharmaceutical developer. Overlaps with Cannatrek on medicinal cannabis distribution and shares exposure to TGA-regulated prescriber pathways.
BOD Australia: Australian medicinal cannabis and hemp-derived CBD product company selling through healthcare professionals and pharmacies. Comparable prescriber-focused distribution model in the same regulatory environment.

Emerging players

MGC Pharmaceuticals: Australia-listed medicinal cannabis company with operations spanning Europe and Australia. Comparable in product category but operates at smaller scale and across multiple geographies, making it an emerging rather than direct peer.
Zelira Therapeutics: Australian-listed company developing clinically validated cannabinoid-based medicines. Comparable therapeutic-goods positioning but more R&D-focused and earlier-stage in commercial distribution than Cannatrek.

Broad incumbents

Tilray Brands: Global vertically integrated cannabis company with cultivation, processing, and distribution across multiple continents including Australia. Much larger incumbent that overlaps with Cannatrek on medicinal cannabis products and pharmacy distribution.
Aurora Cannabis: Global cannabis producer with medicinal cannabis operations in multiple countries. A broad incumbent peer with overlapping medicinal product lines and prescriber-channel distribution, though much larger and more diversified than Cannatrek.
Canopy Growth Corporation: Large global cannabis company with established medicinal cannabis brands distributed via pharmacies and prescribers. Broad incumbent that competes for the same medicinal patient populations as Cannatrek in markets where it operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cannatrek compliance and trust

Trust signal

Compliance1 record

Cannatrek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cannatrek leadership team

Management profile

Number of profiles

Cannatrek funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cannatrek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cannatrek

What does Cannatrek do?

Is Cannatrek a public or private company?

Cannatrek is a private company. It is classified as unknown and is currently operating.

When was Cannatrek founded?

Cannatrek was founded in 2014. It employs 51 to 100 people.

Where is Cannatrek based?

Cannatrek is headquartered in Balaclava, Australia, in the Oceania region.

How does Cannatrek make money?

One revenue line is on record: medicinal cannabis products and services.

Who are Cannatrek's main competitors?

Direct peers on record are Little Green Pharma, Althea Group Holdings, AusCann Group Holdings, Incannex Healthcare and BOD Australia. Emerging players are MGC Pharmaceuticals and Zelira Therapeutics. Broad incumbents are Tilray Brands, Aurora Cannabis and Canopy Growth Corporation.

Does Cannatrek have an API?

No public API is recorded for Cannatrek.

What industry is Cannatrek in?

Cannatrek's product category is Medicinal Cannabis Manufacturing. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.